Caveats of caveolin-1 in cancer progression
Elke Burgermeister(Heidelberg University), Matthias Ebert(University of Mannheim), Christoph Röcken(University Hospital Schleswig-Holstein), Mordechai Liscovitch(Weizmann Institute of Science), Roland M. Schmid(Tumkur University)
Cited by 140
Related Papers
Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B.
|Journal of Clinical Investigation|1998|737
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Phospholipase D: molecular and cell biology of a novel gene family
|Biochemical Journal|2000|492
Lipid second messengers
|Cell|1994|358
Up-regulation of Caveolae and Caveolar Constituents in Multidrug-resistant Cancer Cells
|Journal of Biological Chemistry|1998|294